Shionogi goes down Niemann-Pick avenue for new cholesterol candidate
This article was originally published in Scrip
Executive Summary
Apparently preparing for the day when its substantial royalty stream from Crestor (rosuvastatin) begins to decline, Shionogi has acquired global development, manufacturing and commercialisation rights to a cholesterol-lowering candidate from Japan's Kotobuki Pharmaceutical.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Catchup Capsule: Key APAC Insights You Need To Read
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Need a specific report? 1000+ reports available
Buy Reports